[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Taipei Medical University WanFang Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":311},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,44,69,95,120,143,171,194,214,235,260,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100607700","efficacy-of-an-afcn-proxy-block-in-post-tka-multimodal-pain-management-100607700",false,"NCT07191964","Efficacy of an AFCN Proxy Block in Post-TKA Multimodal Pain Management","Efficacy Assessment of Supra-Sartorial Subcutaneous Infiltration (SSSI) as an Anterior Femoral Cutaneous Nerve Proxy Block in the Multimodal Pain Management After Total Knee Arthroplasty: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 45-90 undergoing unilateral primary TKA for osteoarthritis.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Able to provide informed consent and use NRS pain scales.\n* Surgery scheduled to start before noon to standardize spinal anesthesia recovery.\n\nExclusion Criteria:\n\n* Bilateral or revision TKA.\n* Contraindications to regional anesthesia (e.g., coagulopathy, infection at injection site).\n* Chronic opioid use (\\>30 mg morphine equivalents\u002Fday) or preoperative NRS \\>4.\n* Pre-existing neurological deficits in lower extremities or AFCN-related neuropathy.\n* Allergy to ropivacaine.\n* Pregnancy, breastfeeding, or cognitive impairment affecting assessments.","ALL","45 Years","90 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial evaluates the additive effect of Supra-Sartorial Subcutaneous Infiltration (SSSI) when performed in combination with intermittent adductor canal block (iACB) and posterior capsule local infiltration analgesia (PC-LIA) for pain management after total knee arthroplasty (TKA). SSSI, an easy-to-perform tentative proxy block to targeted anterior femoral cutaneous nerve (AFCN) block, is tested in 90 adults (45-90 years) randomized into two arms: active SSSI versus sham SSSI. Primary outcome is pain scores at rest and during movement on postoperative day 0; secondary outcomes include daily pain trajectory at rest and during movement, functional recovery scores, rescue analgesic doses over days 0-3, and quality of recovery assessment on day 4.",[27],"Postoperative Pain Management in Total Knee Arthroplasty",[29,30],"Anterior Femoral Cutaneous Nerve Block","Total Knee Arthroplasty","NOT_YET_RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":21},"2026-08-01",{"date":39,"type":21},"2027-09-01",{"name":41,"class":42},"Taipei Medical University WanFang Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100637836","microneedling-for-androgenic-alopecia-a-clinical-study-100637836","NCT07580521","Microneedling for Androgenic Alopecia: a Clinical Study","Microneedling for Androgenic Alopecia: A Clinical Study","Inclusion Criteria:\n\n* Patients aged ≥22 years\n* Mild to moderate androgenic alopecia (for males, Norwood's grading II-IV, and for females, Ludwig stage I-II.)\n\nExclusion Criteria:\n\n* Presence of obvious scalp wounds or other dermatologic lesions, including papulopustular rosacea, stage III-IV acne, eczema, herpes simplex, warts, scleroderma, bacterial or fungal infections, open wounds, actinic keratosis, or skin cancer\n* Alopecia other than androgenetic alopecia\n* Unilateral or uneven hair loss\n* History of keloid formation or keloid tendency\n* Pregnant women\n* Patients with HIV infection\n* Coagulation abnormalities (international normalized ratio \\[INR\\] \\> 1.2, activated partial thromboplastin time \\[aPTT\\] \\> 40 seconds), thrombocytopenia (\\\u003C 100,000\u002FμL), hemophilia, or current use of antiplatelet or anticoagulant medications\n* Patients with hepatitis B, hepatitis C, acquired immunodeficiency, or cancer\n* Patients using a cardiac pacemaker or other similar implantable medical devices\n* Patients using extracorporeal membrane oxygenation (ECMO) or other types of life-support equipment\n* Patients using medical devices with electrocardiographic monitoring functions","22 Years",{"count":53,"type":21},25,[24],"A total of 20-30 patients with mild to moderate androgenic alopecia are expected to be enrolled. Inclusion criteria are patients aged ≥22 years; for males, Norwood's grading II-IV, and for females, Ludwig stage I-II. After enrollment, one researcher will use computer-generated randomization to assign each side of the patient's scalp to either the experimental group or the control group. The scalp side allocated to the experimental group will receive microneedling treatment once every two weeks (at baseline, and at weeks 2, 4, 6, 8, and 10; six sessions in total). The control side of the scalp will not receive microneedling or any topical treatment.\n\nTreatment efficacy will be evaluated at baseline and at weeks 4, 8, 12, and 24 after trial initiation. Evaluation methods include trichoscopy and standardized photography. Photographs will be reviewed by assessing physicians to determine follicular density, hair density, hair thickness, the ratio of vellus to terminal hairs, and physician global assessment. The evaluating physicians will be blinded to which side is the experimental group and which side is the control group.\n\nAt Weeks 12 and 24 after the initiation of the study, the evaluating physician will perform the Physician Global Assessment (PGA) scale based on the captured photographs. In addition, patient satisfaction with the treatment will be assessed through physician-administered interviews using the Patient Global Assessment scale.",[57],"Androgenic Alopecia",[59,60],"androgenic alopecia","microneedling","2026-05-06",{"date":63,"type":35},"2026-05-12",{"date":65,"type":21},"2026-05-01",{"date":67,"type":21},"2026-12-31",{"name":41,"class":42},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":73,"conditions":82,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":43},"100631549","effect-of-the-ems-back-up-ergonomic-program-on-paramedics-manual-handling-safety-100631549","NCT07502131","Effect of the \"EMS Back-Up\" Ergonomic Program on Paramedics' Manual Handling Safety.","Investigation on the Benefit of a Structured Manual Handling Training Program Regarding Paramedics' Technical Proficiency, Knowledge, and Behavioral Intentions on Clinical Practice Safety.","Inclusion Criteria:\n\n1. Frontline Emergency Medical Technicians (EMTs) or paramedics.\n2. Active duty personnel involved in patient handling and transport.\n\nExclusion Criteria:\n\n1. Non-frontline personnel (administrative only).\n2. Students or trainees not yet in clinical practice.",true,"20 Years","65 Years",{"count":80,"type":21},60,[24],[83,84,85],"Ergonomics","Occupational Injuries","EMS Exposures or Injuries of EMS Personnel","RECRUITING","2026-03-24",{"date":89,"type":35},"2026-03-30",{"date":91,"type":21},"2026-03",{"date":93,"type":21},"2026-12",{"name":41,"class":42},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":76,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":43},"100623775","the-effects-of-rosuvastatin-on-running-training-adaptation-and-safety-100623775","NCT07401017","The Effects of Rosuvastatin on Running Training Adaptation and Safety","The Effects of Rosuvastatin on Physiological Adaptation and Safety During Regular Long-Distance Running Training: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Meets clinical criteria for statin therapy, including at least one of the following:\n* Family history of hyperlipidemia.\n* LDL-C ≥ 160 mg\u002FdL.\n* 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk ≥ 7.5%\n* Diabetes mellitus with LDL-C ≥ 70 mg\u002FdL.\n* Determined by a clinician to require lipid-lowering therapy.\n* Currently using or eligible to initiate rosuvastatin therapy.\n* Performs long-distance running at least 3 times per week and is willing to maintain regular training for 3 months.\n* Able and willing to undergo cardiopulmonary exercise testing (CPET) and to record training data using a sports watch (for TRIMP calculation).\n* No known drug allergies and provides written informed consent after study explanation.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to statins or rosuvastatin.\n* History of severe statin-related adverse events, including rhabdomyolysis or marked creatine kinase (CK) elevation.\n* Liver dysfunction with AST or ALT \\> 3× upper limit of normal.\n* Moderate to severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* Current lower-limb pain, tendon injury, or other conditions that prevent running training.\n* Not suitable for maximal cardiopulmonary exercise testing (CPET), such as unstable angina, uncontrolled hypertension, or recent cardiovascular events.\n* Pregnant or breastfeeding.\n* Inability to comply with study procedures, including use of a sports watch, regular follow-up visits, or maintaining running training.","18 Years",{"count":104,"type":21},40,[24],"Statins lower low-density lipoprotein cholesterol (LDL-C) and help prevent atherosclerotic cardiovascular disease, but some users develop statin-associated muscle symptoms (SAMS) such as soreness, stiffness, weakness, or elevated creatine kinase (CK). These symptoms may be more noticeable during exercise. Regular long-distance running improves cardiopulmonary fitness-VO₂max, aerobic threshold (AT), and respiratory compensation point (RCP)-mainly through mitochondrial and metabolic adaptations. Prior studies suggest that lipophilic statins like simvastatin may blunt these adaptations, while hydrophilic statins such as rosuvastatin may have a smaller impact. However, prospective data in habitual endurance runners are limited.\n\nThis randomized controlled trial will examine how rosuvastatin affects cardiopulmonary fitness improvements and muscle tolerance in individuals who run at least three times per week and meet clinical criteria for statin therapy. After informed consent and baseline cardiopulmonary exercise testing (CPET), participants will be randomized to rosuvastatin 10 mg daily or no statin therapy for three months. Both groups will maintain their usual training routines, and training load will be recorded using heart-rate-based TRIMP. CPET will be repeated monthly to assess changes in VO₂max, AT, and RCP, and muscle enzymes and SAMS will be evaluated at each visit.\n\nThe study aims to clarify whether rosuvastatin influences endurance-related physiological adaptations or increases muscle symptoms in regular long-distance runners.",[108,109,110,111],"Dyslipidemia","Long-Distance Running","Endurance Training","Statin-Associated Muscle Symptoms","2026-02-05",{"date":114,"type":35},"2026-02-10",{"date":116,"type":21},"2026-03-01",{"date":118,"type":21},"2026-10-31",{"name":41,"class":42},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":76,"sex":16,"minAge":102,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100621047","the-effectiveness-of-gamified-scenario-based-teaching-in-improving-nurses-awareness-and-confidence-in-clinical-emergency-care-100621047","NCT07365540","The Effectiveness of Gamified Scenario-based Teaching in Improving Nurses' Awareness and Confidence in Clinical Emergency Care","According to the WANFANG H Holistic Care Program - Clinical Training Group 113-WFHHCE-03 Program, Studies With a Start Date Before July 31, 2026, Are Eligible for the Relevant Criteria.。","Convenience sampling was adopted, and the inclusion criteria included: nurses with more than 3 months of experience working in general wards; the exclusion criteria included: nurses in pediatric-related wards (including neonatal observation rooms and pediatric intensive care units).","50 Years",{"count":129,"type":21},68,[24],"Research Objective: This study aims to explore the effectiveness of gamified situational teaching in improving nurses' awareness and confidence in clinical emergency response.",[133],"Education","2026-01-16",{"date":136,"type":35},"2026-01-26",{"date":138,"type":21},"2026-01-01",{"date":140,"type":21},"2026-04",{"name":41,"class":42},3,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":151,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},"100615502","pelvic-floor-muscle-exercise-for-lower-urinary-tract-symptoms-after-surgery-for-benign-prostatic-hyperplasia-100615502","NCT07293442","Pelvic Floor Muscle Exercise for Lower Urinary Tract Symptoms After Surgery for Benign Prostatic Hyperplasia.","Effects of Pelvic Floor Muscle Exercise on Lower Urinary Tract Symptoms, Postvoid Residual Volume and Quality of Life in Patients Undergoing Surgery for Benign Prostatic Hyperplasia.","BPH LUTS PFME","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Diagnosed with benign prostatic hyperplasia (BPH) and scheduled to undergo their first prostate surgery.\n3. Able to communicate in Mandarin or Taiwanese.\n\nExclusion Criteria:\n\n1. Patients with prostate cancer, bladder tumors, or other concomitant urological diseases.\n2. Patients with long-term indwelling urinary catheters or suprapubic cystostomy.\n3. Patients currently participating in other urology-related clinical trials.","MALE","18 Months","99 Months",{"count":155,"type":21},46,[24],"This study aims to evaluate the effectiveness of pelvic floor muscle exercise (PFME) on improving lower urinary tract symptoms (LUTS), postvoid residual volume (PVR), and quality of life in patients undergoing surgery for benign prostatic hyperplasia (BPH). Patients who undergo BPH-related procedures, such as TURP or HoLEP, often experience postoperative symptoms including urinary urgency, frequency, nocturia, dribbling, and voiding difficulty, which may negatively affect daily living. Pelvic floor muscle exercise is believed to enhance urethral sphincter function and pelvic floor support, thereby improving urinary control. This randomized study assigns participants to either an intervention group receiving PFME training or a control group receiving standard postoperative care. Differences in urinary outcomes between groups will be compared. The findings are expected to provide an accessible and cost-effective rehabilitation strategy to support postoperative recovery and quality of life.",[159],"Benign Prostatic Hyperplasia",[161],"LUTS, Quality of Life","2025-12-22",{"date":164,"type":35},"2025-12-23",{"date":166,"type":35},"2025-12-19",{"date":168,"type":21},"2026-07-31",{"name":41,"class":42},2,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":4},"100604489","shared-decision-making-for-families-in-critical-dialysis-initiation-100604489","NCT07150182","Shared Decision-Making for Families in Critical Dialysis Initiation","The Integrated Shared Decision-making Program of Critical Hemodialysis Initiation - the Effects on Decision Conflict, Decision Regret, Anxiety and Depression Among Family Members","Inclusion Criteria:\n\n(A)Patients: (1)Age ≥ 20 years. (2)Admitted to the ICU. (3)Diagnosed with acute kidney injury (AKI) requiring urgent hemodialysis. (4)No medical disputes occurred during the current hospitalization. (B) Family members:\n\n1. Age ≥ 20 years.\n2. Mentally alert and able to communicate in Mandarin or Taiwanese.\n3. Key person for the patient's admission (primary contact between patient, family, and medical team).\n4. Willing to participate in the clinical trial.\n\nExclusion Criteria:\n\n(A) Patients:\n\n1. Age \\\u003C 20 years.\n2. End-stage kidney disease already receiving renal replacement therapy (including hemodialysis, peritoneal dialysis, or kidney transplantation). (B) Family members:\n\n(1)Unable to comply with study procedures. (2)Rarely visiting the patient (less than once every three days). (3)History of alcohol or substance abuse, mental disorders, or cognitive impairment affecting participation.","99 Years",{"count":180,"type":21},100,[24],"Background:Acute kidney injury (AKI) is a frequent and serious complication in critically ill patients, often necessitating difficult decisions about starting hemodialysis. While shared decision-making (SDM) is known to improve communication, the effectiveness of structured SDM programs specifically designed for family members in this critical context is not well-established.\n\nAims: The primary purpose of this study is to evaluate the effectiveness of a structured shared decision-making (SDM) program for family members of patients requiring critical hemodialysis initiation. We will assess the program's impact on the quality of the decision-making process (e.g., decision conflict, regret) and the psychological well-being (e.g., anxiety, depression) of the family members.\n\nMethods: This study is a parallel-group, randomized controlled trial. Eligible participants (family members of patients with AKI initiating hemodialysis) will be randomly assigned to either an intervention group or a control group. The intervention group will receive a structured SDM support program, while the control group will receive standard care. Primary outcomes, including decision conflict, decision regret, anxiety, and depression, will be measured at baseline and follow-up. Data will be analyzed using the generalized estimating equation (GEE) model to compare the effectiveness between the two groups.",[184,185,186],"Acute Kidney Injury","Decision Making ,Shared","Emotional Dysfunction","2025-08-29",{"date":189,"type":35},"2025-09-02",{"date":191,"type":21},"2025-10-01",{"date":67,"type":21},{"name":41,"class":42},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":76,"sex":16,"minAge":77,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":43},"100582360","prospective-study-between-polysomnography-psg-and-novel-ultrasonic-jaw-tracking-device-in-patients-with-sleep-apnea-100582360","NCT06862297","Prospective Study Between Polysomnography (PSG) and Novel Ultrasonic Jaw Tracking Device in Patients with Sleep Apnea","Prospective Study on Concurrent Use of Multiple Polysomnography (PSG) Parameters and a Novel Ultrasonic Jaw Tracking Device in Patients with Sleep Apnea","Inclusion Criteria:\n\n1. Subjects aged between 20 and 75 years.\n2. Potential sleep apnea cases: individuals referred by healthcare professionals due to suspected sleep apnea. Indicators may include excessive daytime sleepiness, noticeable loud snoring, witnessed apneas, or high-risk assessments on standard sleep apnea screening questionnaires.\n3. Subjects assessed by healthcare professionals to require polysomnography (PSG) evaluation.\n4. Subjects willing to sign the informed consent form and have been informed about the trial procedures. Participants must have the psychological capacity to provide informed consent and comply with study protocols.\n5. Subjects agree that the principal investigator and their medical team may review their past medical records and extract sleep apnea-related medical history into the case report form during their participation in the trial, as per the condition or trial needs.\n\nExclusion Criteria:\n\n1. Patients currently receiving treatment for sleep apnea (e.g., CPAP therapy or oral appliances) who cannot sleep without these devices or face potential risks without them.\n2. Major respiratory risk conditions: including patients with chronic obstructive pulmonary disease (COPD), unstable asthma, or other significant respiratory conditions that may affect the accuracy of sleep study results should be excluded.\n3. Patients with unstable cardiac conditions or recent hospitalization related to cardiac issues should be excluded from this clinical trial for the safety of conducting sleep assessments.\n4. Patients taking medications that may interfere with sleep patterns or muscle tone (e.g., sedatives or muscle relaxants) should be excluded from the study.\n5. Patients with physical abnormalities or conditions that may interfere with the placement or function of the mandibular tracking device (e.g., noticeable facial hair, dental appliances, or severe dental problems) should be excluded.\n6. Individuals with neurological conditions that may affect mandibular muscle control or present symptoms similar to sleep apnea (e.g., Parkinson's disease, severe post-stroke neurological damage).\n7. Patients diagnosed with DSM-IV and DSM-V disorders and any other potential emotional issues or psychological history.\n8. Other exclusions as determined by the principal investigator\u002Fsleep technician who deems the subject unsuitable for participation in the trial.","75 Years",{"count":180,"type":21},[24],"Obstructive sleep apnea (OSA) affects over 936 million adults worldwide, leading to significant morbidity and reduced quality of life. Traditional diagnostic methods such as polysomnography (PSG), although effective, rely on hospital equipment and human resources and are not widely accessible. Emerging technologies such as the jaw tracking device developed by Sunrise have appeared, using gyroscopes and accelerometers to monitor jaw movements during sleep, showing high diagnostic accuracy compared to PSG. These devices use AI algorithms, providing a practical alternative for OSA diagnosis and monitoring. However, due to the high hardware cost of Sunrise and its rental-based business model, there are logistical challenges and limited monitoring capabilities. This prospective clinical study aims to offer the same capabilities through a novel ultrasonic transmitter for tracking jaw movements during sleep, which can be directly received by using a smartphone microphone, reducing the complexity of setup operations. This study will evaluate the sensitivity of the ultrasonic jaw tracking device in detecting apnea and compare it with PSG standards, developing a deep learning AI-driven algorithm to analyze data from jaw movements, breathing sounds, and apnea-related arousal events, as a basis for continuous home monitoring and evaluation of treatment effects for OSA patients.",[206],"Obstructive Sleep Apnea","2025-03-02",{"date":209,"type":35},"2025-03-06",{"date":211,"type":35},"2024-09-19",{"date":189,"type":21},{"name":41,"class":42},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":127,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":43},"100576297","ai-driven-cognitive-digital-therapeutics-for-dementia-management-100576297","NCT06783465","AI-Driven Cognitive Digital Therapeutics for Dementia Management","AI-Driven Generative Content and Precision Dynamic Executive Function Cognitive Digital Therapeutics System for Dementia Management","Inclusion Criteria:\n\n1. Age at least 50 years old.\n2. Clinical Dementia Rating from 0.5-1\n3. Physician diagnosed mild neurocognitive disorder or dementia (according to ICD-11 diagnostic criteria)\n\nExclusion Criteria:\n\n1. Mini-mental state examination score below 18\n2. If receiving an approved Alzheimer's disease treatment such as acetylcholinesterase inhibitor (AChEIs) or memantine or both for Alzheimer's disease, must be on a stable dose for at least 4 weeks prior to Baseline.\n3. Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's mild neurocognitive disorder or dementia.\n4. History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening.\n5. Any psychiatric diagnosis or symptoms (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant.\n6. Geriatric Depression Scale (GDS) score greater than or equal to 10 at Screening.\n7. Participants who were dosed in a clinical study involving any new chemical entities for AD within 6 months prior to screening unless it can be documented that the participant was in a placebo treatment arm.",{"count":222,"type":21},30,[24],"The study would investigate the effect of a cognitive digital therapeutics system. The intervention group would receive three digital therapeutics sessions per week for 8 weeks, while the control group would receive usual care. Evaluations would be done at baseline, week 8, and week 16.",[226],"Cognitive Impairment","2025-02-17",{"date":229,"type":35},"2025-02-19",{"date":231,"type":35},"2025-02-01",{"date":233,"type":21},"2026-06",{"name":41,"class":42},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":43},"100514004","effects-of-home-based-surface-electrical-stimulation-for-patients-with-cervical-myofascial-pain-syndrome-100514004","NCT05972837","Effects of Home-based Surface Electrical Stimulation for Patients with Cervical Myofascial Pain Syndrome","Inclusion Criteria:\n\n* Time of using computer \\> 4hrs\u002Fday\n* Neck pain \\> 2 months\n* Diagnosis of cervical myofascial pain syndrome\n* VAS pain ≥ 3 (0\\~10)\n\nExclusion Criteria:\n\n* Had a history of neck surgery\n* Pregnancy\n* Systematic disease (e.g. autoimmune disorders, arthritis, infection, etc.)\n* Malignancy\n* Neurological signs such as radiating pain, motor weakness in the upper extremities.\n* Skin defect or scars at the planned placement of SES\n* Pacemaker user\n* History of seizure attack\n* History of diabetes\n* Fear of receiving SES","60 Years",{"count":80,"type":21},[24],"The aim of this study is to compare the developed home-based surface electrical stimulation program to the controls in computer office workers with MPS.",[246],"Myofascial Pain Syndrome of Neck",[248,249,250,251],"Myofascial Pain Syndromes","Surface electrical stimulation","Remote medical support","Telemedicine","2025-01-15",{"date":254,"type":35},"2025-01-17",{"date":256,"type":35},"2023-08-04",{"date":258,"type":21},"2025-11-01",{"name":41,"class":42},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100556510","phase-3-a-short-regimen-for-rifampicin-resistant-isoniazid-susceptible-tb-100556510","NCT06526039","A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB","A Short Regimen for Patients With Rifampicin-resistant Isoniazid-susceptible Tuberculosis","Inclusion Criteria:\n\nA patient will be eligible for entry to the study if he\u002Fshe:\n\n* Is willing and able to give informed consent to be enrolled in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate)\n* Is aged 18 years or older\n* Has bacteriologically-confirmed pulmonary tuberculosis by Xpert MTB\u002FRIF, other nucleic acid amplification test, or culture\n* With initial laboratory result of resistance to rifampicin by Xpert MTB\u002FRIF or Xpert MTB\u002FRIF ultra, or other DST (line probe assay, culture); and with initial laboratory result that is susceptible to isoniazid by Xpert MTB\u002FRIF or other DST. If rifampicin resistance is detected by Xpert MTB\u002FRIF or Xpert MTB\u002FRIF ultra in specimens with very low bacillary, rifampicin resistance has been confirmed by a repeat molecular test.\n* With initial laboratory result of being susceptible to rifampicin by Xpert MTB\u002FRIF or other DST (Xpert MTB\u002FRIF ultra, line probe assay, culture) but are not able to tolerate rifampicin for whom rifabutin is intolerable or clinically not indicated; and with initial laboratory result that is susceptible to isoniazid by Xpert MTB\u002FRIF or other DST\n* With initial laboratory result of being susceptible to rifampicin by Xpert MTB\u002FRIF or other DST (Xpert MTB\u002FRIF ultra, line probe assay, culture) but rifamycin-sparing regimens are preferred due to drug-drug interaction, such as organ transplant recipients; and with initial laboratory result that is susceptible to isoniazid by Xpert MTB\u002FRIF or other DST.\n* With initial laboratory result that is susceptible to fluoroquinolone by Xpert MTB\u002FXDR or other DST.\n* If HIV test positive, is willing to be treated with ART in accordance with the national policies.\n* Agrees to use effective barrier contraception or have an intrauterine contraceptive device during treatment phase if a pre-menopausal woman\n* Has an identifiable address and expects to remain in the area for the duration of the study\n* Is willing to adhere to the follow-up schedule and to study procedures\n\nExclusion Criteria:\n\nA patient will not be eligible for entry to the study if he\u002Fshe:\n\n* Is infected with a strain of M. Tuberculosis resistant to isoniazid by Xpert MTB\u002FXDR or other tests\n* Is infected with a strain of M. Tuberculosis resistant to fluoroquinolone by Xpert MTB\u002FXDR or other tests\n* Is infected with a strain of M. Tuberculosis resistant to amikacin by Xpert MTB\u002FXDR or other tests and have no result of susceptibility of isoniazid by conventional drug susceptibility testing\n* Has tuberculous meningitis or bone and joint tuberculosis\n* Is critically ill, and in the judgment of the investigator, unlikely to survive more than 4 months.\n* Is known to be pregnant or breast-feeding\n* Is unable to attend or comply with treatment or follow-up schedule\n* Is unable to take oral medication\n* Has AST or ALT \\>5 times the upper limit of normal\n* Has AST or ALT \\> 3 times the upper limit of normal ,and either with symptoms of hepatitis or bilirubin \\> 1.5 times the upper limit of normal\n* Has any condition (social or medical) which in the opinion of the investigator would make study participation unsafe.\n* Is taking any medications contraindicated with the medicines in either the trial or control regimen\n* Has a known allergy to any fluoroquinolone antibiotic\n* Is currently taking part in another trial of a medicinal product\n* Has a QTcF interval of ≥450msec at screening",{"count":180,"type":21},[269],"PHASE3","To assess outcome of treatment and safety among patients with rifampicin-resistant isoniazid-susceptible pulmonary tuberculosis treated with a novel regimen consisting of isoniazid, bedaquiline, and moxifloxacin throughout for 6 months, supplemented by pyrazinamide for the initial 2 months.",[272],"Tuberculosis, Pulmonary",[274,275,276,277,278],"bedaquiline","isoniazid","moxifloxacin","tuberculosis","rifampicin resistance","2024-07-24",{"date":281,"type":35},"2024-07-29",{"date":283,"type":21},"2024-07",{"date":285,"type":21},"2029-12",{"name":41,"class":42},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":76,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100550629","applying-videos-feedback-learning-to-improve-skills-performance-of-physiotherapy-interns-100550629","NCT06449560","Applying Videos Feedback Learning to Improve Skills Performance of Physiotherapy Interns","Department of Physical Medicine and Rehabilitation, Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan","Inclusion Criteria:\n\n* physical therapy interns require individuals to be over 20 years old.\n\nExclusion Criteria:\n\n* Individuals unwilling to participate in the study.",{"count":20,"type":21},[24],"This project uses self-practicing videos feedback to learn to improve the skill performance of physiotherapy interns. For traditional physiotherapy intern courses, teachers will conduct core courses and demonstrate teaching, but students are less familiar with the application of skills, even if adding practice course. The learning outcomes of the course are still not good in skill performance. By recording the self-practicing videos, the teacher uses observation and feedback to let the physiotherapy interns know whether the posture of the individual case, the fixed position of the limbs are appropriate, the resistance given and whether the verbal instruction is correct, and based on the evaluation outcomes to observe the students' learning status and clinical thinking ability can improve the skill performance and learning satisfaction.",[298],"Feedback",[300,301,302],"Videos Feedback","Skills Performance","Physiotherapy","2024-06-05",{"date":305,"type":35},"2024-06-10",{"date":307,"type":21},"2024-07-01",{"date":309,"type":21},"2026-05-31",{"name":41,"class":42},""]